Federal Court Okays Remicade Biosimilar

A federal court ruled Pfizer can continue to market its biosimilar for Johnson & Johnson’s immunosuppressant drug Remicade (infliximab).

J&J subsidiary Janssen sued Celltrion, the biosimilar’s South Korean manufacturer, and the Pfizer subsidiary Hospira in 2015 over their biosimilar Inflectra, claiming it infringed on a Janssen-owned patent.

On July 30, the U.S. District Court of Massachusetts ruled in favor of Celltrion and Hospira, removing the final legal barrier to the continued marketing of Inflectra.